We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
- Authors
Prey, S; Ezzedine, K; Doussau, A; Grandoulier, A-S; Barcat, D; Chatelus, E; Diot, E; Durant, C; Hachulla, E; de Korwin-Krokowski, J-D; Kostrzewa, E; Quemeneur, T; Paul, C; Schaeverbeke, T; Seneschal, J; Solanilla, A; Sparsa, A; Bouchet, S; Lepreux, S; Mahon, F-X; Chene, G; Taïeb, A
- Abstract
Imatinib mesylate is a potent inhibitor of platelet-derived growth factor and transforming growth factor-β signalling pathways which may play a role in systemic sclerosis (SSc)-associated skin changes.
- Publication
The British journal of dermatology, 2012, Vol 167, Issue 5, p1138
- ISSN
1365-2133
- Publication type
Journal Article
- DOI
10.1111/j.1365-2133.2012.11186.x